Stockscreener 앱 받기
5.15
0.39%
-0.02
전일 마감가:
$5.17
열려 있는:
$5.2799
하루 거래량:
1.96M
Relative Volume:
0.44
시가총액:
$463.36M
수익:
$324.00K
순이익/손실:
$-82.10M
주가수익비율:
-5.5376
EPS:
-0.93
순현금흐름:
$-69.18M
1주 성능:
+17.58%
1개월 성능:
+34.11%
6개월 성능:
+381.31%
1년 성능:
+332.77%
1일 변동 폭
$5.09
$5.2799
1주일 범위
$4.80
$5.5264
52주 변동 폭
$0.75
$5.5264
Chimerix Inc Stock (CMRX) Company Profile
명칭
Chimerix Inc
전화
919.806.1074
주소
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
CMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
5.15 | 463.36M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-23 | 개시 | Robert W. Baird | Outperform |
| 2022-09-07 | 개시 | CapitalOne | Overweight |
| 2021-04-29 | 개시 | Maxim Group | Buy |
| 2021-04-23 | 재개 | Cowen | Outperform |
| 2021-03-31 | 개시 | Jefferies | Buy |
| 2021-03-31 | 개시 | Wedbush | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-02-02 | 개시 | H.C. Wainwright | Buy |
| 2016-08-09 | 재확인 | FBR Capital | Mkt Perform |
| 2016-02-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2016-02-23 | 재확인 | FBR Capital | Mkt Perform |
| 2016-02-23 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2016-02-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2015-12-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-28 | 다운그레이드 | FBR Capital | Outperform → Mkt Perform |
| 2015-12-28 | 재확인 | Piper Jaffray | Overweight |
| 2015-12-17 | 개시 | UBS | Buy |
| 2015-10-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-09-03 | 개시 | Citigroup | Buy |
| 2015-08-18 | 개시 | FBR Capital | Outperform |
| 2015-08-06 | 재확인 | Brean Capital | Buy |
| 2015-05-11 | 재확인 | Brean Capital | Buy |
| 2015-03-04 | 개시 | Barclays | Overweight |
| 2015-02-12 | 재확인 | Stifel | Buy |
| 2014-12-31 | 재확인 | Brean Capital | Buy |
| 2014-07-08 | 재개 | Brean Capital | Buy |
모두보기
Chimerix Inc 주식(CMRX)의 최신 뉴스
Vontobel Holding Ltd. Sells 30,000 Shares of Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Chimerix Inc (CMRX)’S 1.77% Increase Makes It Worth Considering Again - Stocks Register
Wedbush Has Positive Outlook for Chimerix FY2025 Earnings - Defense World
Chimerix’s (CMRX) “Buy” Rating Reaffirmed at HC Wainwright - Armenian Reporter
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients (CMRX) - Seeking Alpha
Financial Metrics Unveiled: Chimerix Inc (CMRX)’s Key Ratios in the Spotlight - The Dwinnex
Here's Why Momentum in Chimerix (CMRX) Should Keep going - Nasdaq
What is Wedbush’s Estimate for Chimerix FY2028 Earnings? - Defense World
Evaluating CMRX’s financial ratios for a profitable investment - US Post News
Chimerix stock soars to 52-week high, hits $5.17 - Investing.com India
Chimerix stock soars to 52-week high, hits $5.17 By Investing.com - Investing.com Nigeria
Chimerix Delivers More Than 130% Gain In Less Than 3 Months - RTTNews
Chimerix (NASDAQ:CMRX) Receives Buy Rating from HC Wainwright - Defense World
FDA accepts Chimerix's new drug application for glioma treatment By Investing.com - Investing.com Nigeria
Chimerix’s (CMRX) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Chimerix VP of finance sells $1,359 in stock - MSN
Sector Update: Health Care Stocks Mixed Late Afternoon -February 18, 2025 at 04:06 pm EST - Marketscreener.com
Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise - Marketscreener.com
Chimerix stock gains on FDA review for lead drug (CMRX:NASDAQ) - Seeking Alpha
Wedbush Adjusts Price Target on Chimerix to $7 From $6, Keeps Outperform Rating - Marketscreener.com
Chimerix stock rises on FDA priority review for dordaviprone - Investing.com
Chimerix stock rises on FDA priority review for dordaviprone By Investing.com - Investing.com Nigeria
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma - Marketscreener.com
FDA accepts Chimerix's new drug application for glioma treatment - Investing.com India
Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone - Marketscreener.com
Chimerix CFO sells $10,195 in stock amid tax obligation - MSN
Chimerix CEO Michael Andriole sells $33,282 in stock - MSN
Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock - MarketBeat
Chimerix SVP and general counsel sells $7,226 in stock - MSN
Chimerix VP of finance sells $1,359 in stock By Investing.com - Investing.com Australia
Chimerix CFO sells $10,195 in stock amid tax obligation By Investing.com - Investing.com South Africa
Chimerix CEO Michael Andriole sells $33,282 in stock By Investing.com - Investing.com Nigeria
Chimerix SVP and general counsel sells $7,226 in stock By Investing.com - Investing.com South Africa
Chimerix chief medical officer Melemed sells $13,798 in stock - MSN
Chimerix chief medical officer Melemed sells $13,798 in stock By Investing.com - Investing.com Australia
Chimerix Executives Sell Shares to Cover Tax Liabilities - TradingView
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Peapod Lane Capital LLC Buys Shares of 754,566 Chimerix, Inc. (NASDAQ:CMRX) - MarketBeat
Chimerix stock soars to 52-week high, hits $4.3 - MSN
Chimerix stock soars to 52-week high, hits $4.3 By Investing.com - Investing.com Canada
Check out these key findings about Chimerix Inc (CMRX) - SETE News
Chimerix Inc (CMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Chimerix Inc 주식 (CMRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Andriole Michael T. | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
4.52 |
7,370 |
33,282 |
609,603 |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL |
Feb 13 '25 |
Sale |
4.52 |
1,600 |
7,226 |
213,596 |
| Jakeman David | VP OF FINANCE AND ACCOUNTING |
Feb 13 '25 |
Sale |
4.53 |
300 |
1,360 |
148,987 |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
4.51 |
2,260 |
10,196 |
172,977 |
0.27%
3.05%
자본화:
|
볼륨(24시간):